Literature DB >> 7742045

HTLV-negative and HTLV type I-positive tropical spastic paraparesis in northeastern Brazil.

C M Costa1, P Goubau, H F Liu, A M Vandamme, F M da Cunha, T J Santos, J Desmyter, H Carton.   

Abstract

A type-specific serological survey among 1042 random nonneurological outpatients in two cities in the state of Ceara (northeastern Brazil) shows a low prevalence of HTLV-I (0.34% in Fortaleza; 0.44% in Crato) and of HTLV-II (0.34% in Fortaleza; 0% in Crato). Among 62 chronic myelopathic patients seen in Fortaleza 27 patients were found with clinical features of tropical spastic paraparesis (TSP); 10 of 27 were found HTLV-I seropositive (37%; 95% confidence limits, 19-58%). Proviral genome detection by polymerase chain reaction in 5 seropositive and 12 seronegative patients confirmed the serological findings. This excludes HTLV-I or -II infection as a cause in the seronegative TSP patients. The HTLV-positive and -negative patients did not differ clinically and by history, except that seropositives had a longer mean disease duration, a female predominance, and a higher proportion of white Caucasians. In this population with low HTLV-I and HTLV-II prevalences, HTLV-negative TSP is at least as frequent as the HTLV-I-associated TSP.

Entities:  

Mesh:

Year:  1995        PMID: 7742045     DOI: 10.1089/aid.1995.11.315

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  2 in total

1.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

2.  Human T-cell lymphotropic virus in a population of pregnant women and commercial sex workers in South Western Nigeria.

Authors:  J C Forbi; A B Odetunde
Journal:  Afr Health Sci       Date:  2007-09       Impact factor: 0.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.